|
1
|
Chong DQ and Zhu AX: The landscape of
targeted therapies for cholangiocarcinoma: Current status and
emerging targets. Oncotarget. Apr 18–2016.(Epub ahead of
print).
|
|
2
|
Andersen JB: Molecular pathogenesis of
intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci.
22:101–113. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ching CB and Hansel DE: Expanding
therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway.
Lab Invest. 90:1406–1414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Z, Sun J, Feng Y, Tian X, Wang B and
Zhou Y: Oncogenic roles and drug target of CXCR4/CXCL12 axis in
lung cancer and cancer stem cell. Tumour Biol. 37:8515–8528. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo N, Liu F, Yang L, Huang J, Ding X and
Sun C: Chemokine receptor 7 enhances cell chemotaxis and migration
of metastatic squamous cell carcinoma of head and neck through
activation of matrix metalloproteinase-9. Oncol Rep. 32:794–800.
2014.PubMed/NCBI
|
|
6
|
van der Vorst EP, Döring Y and Weber C:
Chemokines. Arterioscler Thromb Vasc Biol. 35:e52–e56. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ding J and Tredget EE: The role of
chemokines in fibrotic wound healing. Adv Wound Care (New
Rochelle). 4:673–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duda DG, Kozin SV, Kirkpatrick ND, Xu L,
Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway
inhibition: An emerging sensitizer for anticancer therapies? Clin
Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kowalczuk O, Burzykowski T, Niklinska WE,
Kozlowski M, Chyczewski L and Niklinski J: CXCL5 as a potential
novel prognostic factor in early stage non-small cell lung cancer:
Results of a study of expression levels of 23 genes. Tumour Biol.
35:4619–4628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rehman AO and Wang CY: CXCL12/SDF-1 alpha
activates NF-kappaB and promotes oral cancer invasion through the
Carma3/Bcl10/Malt1 complex. Int J Oral Sci. 1:105–118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan
J, Wang X and Li L: CXCL5/CXCR2 axis promotes bladder cancer cell
migration and invasion by activating PI3K/AKT-induced upregulation
of MMP2/MMP9. Int J Oncol. 47:690–700. 2015.PubMed/NCBI
|
|
12
|
von Hundelshausen P, Petersen F and Brandt
E: Platelet-derived chemokines in vascular biology. Thromb Haemost.
97:704–713. 2007.PubMed/NCBI
|
|
13
|
Kalwitz G, Neumann K, Ringe J, Sezer O,
Sittinger M, Endres M and Kaps C: Chondrogenic differentiation of
human mesenchymal stem cells in micro-masses is impaired by high
doses of the chemokine CXCL7. J Tissue Eng Regen Med. 5:50–59.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blunk JA, Sauerstein K and Schmelz M:
Experimental thermal lesions induce beta-thromboglobulin release
from activated platelets. Eur J Pain. 15:23–28. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhuang P, Wo D, Xu ZG, Wei W and Mao HM:
Dynamic changes in plasma tissue plasminogen activator, plasminogen
activator inhibitor-1 and beta-thromboglobulin content in ischemic
stroke. J Clin Neurosci. 22:1123–1127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tai PK, Liao JF, Hossler PA, Castor CW and
Carter-Su C: Regulation of glucose transporters by connective
tissue activating peptide-III isoforms. J Biol Chem.
267:19579–19586. 1992.PubMed/NCBI
|
|
17
|
Kwiatkowski S, Czajka R, Dołegowska B,
Chlubek D and Torbé A: Evaluation of neutrophile elastase and
isoprostane 8epiPGF2alpha concentrations in maternal and umbilical
cord blood serum and in amniotic fluid in pregnancies complicated
by premature rupture of membranes. Ginekol Pol. 79:281–286.
2008.(In Polish). PubMed/NCBI
|
|
18
|
González-Cortés C, Diez-Tascón C,
Guerra-Laso JM, González-Cocaño MC and Rivero-Lezcano OM:
Non-chemotactic influence of CXCL7 on human phagocytes. Modulation
of antimicrobial activity against L. pneumophila. Immunobiology.
217:394–401. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grépin R, Guyot M, Giuliano S, Boncompagni
M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H and
Pagès G: The CXCL7/CXCR1/2 axis is a key driver in the growth of
clear cell renal cell carcinoma. Cancer Res. 74:873–883. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Desurmont T, Skrypek N, Duhamel A,
Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchene B, Ramdane
N, Hebbar M, et al: Overexpression of chemokine receptor CXCR2 and
ligand CXCL7 in liver metastases from colon cancer is correlated to
shorter disease-free and overall survival. Cancer Sci. 106:262–269.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Unver N, Esendagli G, Yilmaz G and Guc D:
CXCL7-induced macrophage infiltration in lung tumor is independent
of CXCR2 expression: CXCL7-induced macrophage chemotaxis in LLC
tumors. Cytokine. 75:330–337. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li B, Qiu T, Zhang P, Wang X, Yin Y and Li
S: IKVAV regulates ERK1/2 and Akt signalling pathways in BMMSC
population growth and proliferation. Cell Prolif. 47:133–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin Y, Cui W, Yang X and Tong B:
Kaempferol inhibits the growth and metastasis of cholangiocarcinoma
in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai).
48:238–245. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilson JM, Kunnimalaiyaan S,
Kunnimalaiyaan M and Gamblin TC: Inhibition of the AKT pathway in
cholangiocarcinoma by MK2206 reduces cellular viability via
induction of apoptosis. Cancer Cell Int. 15:132015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Q, Liu Z, Xie F, Liu C, Shao F, Zhu
CL and Hu S: Fragile histidine triad (FHIT) suppresses
proliferation and promotes apoptosis in cholangiocarcinoma cells by
blocking PI3K-Akt pathway. Sci World J. 2014:1796982014. View Article : Google Scholar
|
|
28
|
Ewald F, Nörz D, Grottke A, Hofmann BT,
Nashan B and Jücker M: Dual inhibition of PI3K-AKT-mTOR- and
RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and
reverses acquired resistance to MEK-inhibitors. Invest New Drugs.
32:1144–1154. 2014. View Article : Google Scholar : PubMed/NCBI
|
